Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02738203 · ClinicalTrials.gov registry record · Phase 3
Self-Administered Lidocaine Gel for Pain Management With IUD Insertion
A Phase 3 study of IUD Insertion, sponsored by Stanford University.
- Completed
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
- 1
- Study location
NCT02738203 is a Phase 3 study of IUD Insertion that has completed, run by Stanford University. The registered enrollment target is 220 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02738203, a Phase 3 study of IUD Insertion, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
- 1
- Study location
Study Summary
For intrauterine device (IUD) insertion, currently there are no standardized clinical guidelines for pain management. The investigators aim to explore whether adequate pain relief is possible through self-administered, non-invasive means alone. Reducing pain associated with IUD insertion may benefit patients and providers. When patients are comfortable during their procedure, it is likely the provider can more quickly and with fewer complications perform the insertion. The investigators propose to explore the effect of a locally applied vaginal lidocaine gel in place of the standard of care pain management, no intervention, prior to IUD insertions. This is a superiority, blinded, randomized controlled trial.
Conditions Studied
Interventions
- DRUG Vaginal 2% Lidocaine
- DRUG Surgical Lubricant Jelly
Study Locations (1)
California
- Stanford Gynecology Clinic - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2016-06-01 |
| Est. Completion | 2017-10-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02738203
The ClinicalTrials.gov registry entry for NCT02738203 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with IUD Insertion appearing as the primary indexed condition, and to 2 interventions - of which Vaginal 2% Lidocaine is the first listed.
NCT02738203 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02738203 about?
NCT02738203 is a clinical study titled "Self-Administered Lidocaine Gel for Pain Management With IUD Insertion". For intrauterine device (IUD) insertion, currently there are no standardized clinical guidelines for pain management. The investigators aim to explore whether adequate pain relief is possible through self-administered, non-invasive means alone. Reducing pain associated with IUD insertion may benefit...
What is the current status of trial NCT02738203?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2016-06-01. Estimated completion is 2017-10-19.
What conditions does trial NCT02738203 study?
This clinical trial studies the following conditions: IUD Insertion.
What interventions are being tested in trial NCT02738203?
The interventions under investigation include: Vaginal 2% Lidocaine (DRUG), Surgical Lubricant Jelly (DRUG).
Who is sponsoring clinical trial NCT02738203?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02738203 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IUD Insertion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.